Kansas City, Kansas, pharmaceutical startup Cingulate Inc. said it has begun Phase 3 testing of what could be its first commercial product.
Cingulate (Nasdaq: CING) said Phase 3 clinical trials have begun of its CTx-1301, for the treatment of attention deficit/hyperactivity disorder (ADHD). Phase 3 testing normally is the final clinical trial step in getting Food and Drug Administration clearance for pharmaceuticals. It involves testing the best adult dosing and effectiveness of the drug, compared…Cingulate begins Phase 3 tests of novel treatment for ADHD
Kansas City, Kansas, pharmaceutical startup Cingulate Inc. said it has begun Phase 3 testing of what could be its first commercial product.
Cingulate (Nasdaq: CING) said Phase 3 clinical trials have begun of its CTx-1301, for the treatment of attention deficit/hyperactivity disorder (ADHD). Phase 3 testing normally is the final clinical trial step in getting Food and Drug Administration clearance for pharmaceuticals. It involves testing the best adult dosing and effectiveness of the drug, compared…